PMID- 20685130
OWN - NLM
STAT- MEDLINE
DCOM- 20120206
LR  - 20110606
IS  - 1879-0461 (Electronic)
IS  - 1040-8428 (Linking)
VI  - 79
IP  - 1
DP  - 2011 Jul
TI  - Can first cycle CBCs predict older patients at very low risk of neutropenia 
      during further chemotherapy?
PG  - 43-50
LID - 10.1016/j.critrevonc.2010.07.001 [doi]
AB  - Elderly cancer patients with normal complete blood cell counts (CBCs) during the 
      first course of (some types of) chemotherapy might be unlikely to experience 
      grade 4 neutropenia during subsequent cycles. In this case, further weekly CBCs 
      might be avoided. We used data of 223 cancer patients aged 70+ who were included 
      in the CRASH (Chemotherapy Risk Assessment Score for High-age patients) trial 
      between 2003 and 2007 in 7 cancer practices in the US. First cycle CBC values 
      were compared to subsequent cycles. MAX2-score was used as a measure for toxicity 
      of the chemotherapy regimen. Sixty-two patients (28%) experienced grade 4 
      neutropenia during subsequent cycles. Among patients who received chemotherapy 
      with a MAX2-score lower than 0.20, only 4.6% of those without neutropenia during 
      the first cycle experienced grade 4 neutropenia during subsequent cycles. Weekly 
      CBC might be avoided in these patients receiving chemotherapy. Future prospective 
      studies should confirm these results.
CI  - Copyright (c) 2010 Elsevier Ireland Ltd. All rights reserved.
FAU - Janssen-Heijnen, Maryska L G
AU  - Janssen-Heijnen ML
AD  - Eindhoven Cancer Registry, Department of Research, Eindhoven, The Netherlands. 
      research@ikz.nl
FAU - Extermann, Martine
AU  - Extermann M
FAU - Boler, Ivette E
AU  - Boler IE
LA  - eng
PT  - Journal Article
DEP - 20100803
PL  - Netherlands
TA  - Crit Rev Oncol Hematol
JT  - Critical reviews in oncology/hematology
JID - 8916049
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
MH  - *Blood Cell Count
MH  - Female
MH  - Humans
MH  - Male
MH  - Neoplasms/complications/*drug therapy/pathology
MH  - Neutropenia/complications/*drug therapy/pathology
MH  - Predictive Value of Tests
MH  - Risk Assessment
EDAT- 2010/08/06 06:00
MHDA- 2012/02/07 06:00
CRDT- 2010/08/06 06:00
PHST- 2009/11/03 00:00 [received]
PHST- 2010/03/02 00:00 [revised]
PHST- 2010/07/07 00:00 [accepted]
PHST- 2010/08/06 06:00 [entrez]
PHST- 2010/08/06 06:00 [pubmed]
PHST- 2012/02/07 06:00 [medline]
AID - S1040-8428(10)00168-X [pii]
AID - 10.1016/j.critrevonc.2010.07.001 [doi]
PST - ppublish
SO  - Crit Rev Oncol Hematol. 2011 Jul;79(1):43-50. doi: 
      10.1016/j.critrevonc.2010.07.001. Epub 2010 Aug 3.